ES2692172T3 - Factores sanguíneos modificados que comprenden un bajo grado de polímero soluble en agua - Google Patents

Factores sanguíneos modificados que comprenden un bajo grado de polímero soluble en agua Download PDF

Info

Publication number
ES2692172T3
ES2692172T3 ES09752930.9T ES09752930T ES2692172T3 ES 2692172 T3 ES2692172 T3 ES 2692172T3 ES 09752930 T ES09752930 T ES 09752930T ES 2692172 T3 ES2692172 T3 ES 2692172T3
Authority
ES
Spain
Prior art keywords
factor
fviii
peg
protein
molecule
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES09752930.9T
Other languages
English (en)
Spanish (es)
Inventor
Peter Turecek
Juergen Siekmann
Hanspeter Rottensteiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Baxalta GmbH
Baxalta Inc
Original Assignee
Baxalta GmbH
Baxalta Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxalta GmbH, Baxalta Inc filed Critical Baxalta GmbH
Application granted granted Critical
Publication of ES2692172T3 publication Critical patent/ES2692172T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/36—Blood coagulation or fibrinolysis factors
    • A61K38/37—Factors VIII
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/482—Serine endopeptidases (3.4.21)
    • A61K38/4846—Factor VII (3.4.21.21); Factor IX (3.4.21.22); Factor Xa (3.4.21.6); Factor XI (3.4.21.27); Factor XII (3.4.21.38)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21021—Coagulation factor VIIa (3.4.21.21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21022—Coagulation factor IXa (3.4.21.22)

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
ES09752930.9T 2008-10-17 2009-10-16 Factores sanguíneos modificados que comprenden un bajo grado de polímero soluble en agua Active ES2692172T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US106424P 1998-10-31
US10642408P 2008-10-17 2008-10-17
PCT/US2009/061023 WO2010045568A1 (en) 2008-10-17 2009-10-16 Modified blood factors comprising a low degree of water soluble polymer

Publications (1)

Publication Number Publication Date
ES2692172T3 true ES2692172T3 (es) 2018-11-30

Family

ID=41650072

Family Applications (1)

Application Number Title Priority Date Filing Date
ES09752930.9T Active ES2692172T3 (es) 2008-10-17 2009-10-16 Factores sanguíneos modificados que comprenden un bajo grado de polímero soluble en agua

Country Status (20)

Country Link
US (4) US20100099616A1 (https=)
EP (3) EP3620177A1 (https=)
JP (2) JP5785872B2 (https=)
KR (2) KR20110071012A (https=)
AU (1) AU2009305612B2 (https=)
BR (1) BRPI0920259A8 (https=)
CA (1) CA2738679A1 (https=)
CY (1) CY1120921T1 (https=)
DK (1) DK2349342T3 (https=)
ES (1) ES2692172T3 (https=)
HR (1) HRP20181454T1 (https=)
HU (1) HUE039906T2 (https=)
LT (1) LT2349342T (https=)
MX (1) MX2011004085A (https=)
NZ (1) NZ592688A (https=)
PL (1) PL2349342T3 (https=)
PT (1) PT2349342T (https=)
SI (1) SI2349342T1 (https=)
SM (1) SMT201800486T1 (https=)
WO (1) WO2010045568A1 (https=)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3093029A1 (en) * 2009-07-27 2016-11-16 Baxalta GmbH Blood coagulation protein conjugates
EP2536753B1 (en) 2010-02-16 2017-12-20 Novo Nordisk A/S Factor viii molecules with reduced vwf binding
GB201007356D0 (en) 2010-04-30 2010-06-16 Leverton Licence Holdings Ltd Conjugated factor VIIa
JP2013532176A (ja) * 2010-07-15 2013-08-15 ノヴォ ノルディスク アー／エス 安定化させた第ｖｉｉｉ因子バリアント
AU2012311484B2 (en) 2011-09-23 2017-04-13 Novo Nordisk A/S Novel glucagon analogues
MY190257A (en) 2012-04-16 2022-04-11 Cantab Biopharmaceuticals Patents Ltd Optimised subcutaneous therapeutic agents
EP2986313B1 (en) 2013-04-18 2019-06-12 Novo Nordisk A/S Stable, protracted glp-1/glucagon receptor co-agonists for medical use
US10570184B2 (en) 2014-06-04 2020-02-25 Novo Nordisk A/S GLP-1/glucagon receptor co-agonists for medical use
CN106687126B (zh) 2014-08-04 2020-07-28 杰特有限公司 因子viii制剂
ES2772933T3 (es) 2015-03-06 2020-07-08 CSL Behring Lengnau AG Factor de von Willebrand modificado que tiene una semivida mejorada
JP6552286B2 (ja) * 2015-06-05 2019-07-31 公立大学法人奈良県立医科大学 凝固第ｖｉｉｉ因子の複合体形成能に関する情報の取得方法および試薬キット
WO2021001522A1 (en) 2019-07-04 2021-01-07 CSL Behring Lengnau AG A truncated von willebrand factor (vwf) for increasing the in vitro stability of coagulation factor viii
US20220348637A1 (en) 2019-11-11 2022-11-03 CSL Behring Lengnau AG Polypeptides for inducing tolerance to factor viii

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) * 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US4757006A (en) * 1983-10-28 1988-07-12 Genetics Institute, Inc. Human factor VIII:C gene and recombinant methods for production
US4970300A (en) 1985-02-01 1990-11-13 New York University Modified factor VIII
US6048729A (en) 1987-05-01 2000-04-11 Transkaryotic Therapies, Inc. In vivo protein production and delivery system for gene therapy
US5122614A (en) * 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5252714A (en) 1990-11-28 1993-10-12 The University Of Alabama In Huntsville Preparation and use of polyethylene glycol propionaldehyde
US6063630A (en) 1991-11-05 2000-05-16 Transkaryotic Therapies, Inc. Targeted introduction of DNA into primary or secondary cells and their use for gene therapy
US6037452A (en) 1992-04-10 2000-03-14 Alpha Therapeutic Corporation Poly(alkylene oxide)-Factor VIII or Factor IX conjugate
US5298643A (en) * 1992-12-22 1994-03-29 Enzon, Inc. Aryl imidate activated polyalkylene oxides
WO1994015625A1 (en) 1993-01-15 1994-07-21 Enzon, Inc. Factor viii - polymeric conjugates
US5621039A (en) * 1993-06-08 1997-04-15 Hallahan; Terrence W. Factor IX- polymeric conjugates
US5824784A (en) * 1994-10-12 1998-10-20 Amgen Inc. N-terminally chemically modified protein compositions and methods
US6238908B1 (en) 1995-06-07 2001-05-29 Aastrom Biosciences, Inc. Apparatus and method for maintaining and growth biological cells
US7074878B1 (en) 1999-12-10 2006-07-11 Harris J Milton Hydrolytically degradable polymers and hydrogels made therefrom
US20030211094A1 (en) * 2001-06-26 2003-11-13 Nelsestuen Gary L. High molecular weight derivatives of vitamin k-dependent polypeptides
UA86744C2 (en) * 2002-06-21 2009-05-25 Ново Нордиск Хэлс Кеа Аг Pegylated factor vii glycoforms
WO2004056852A2 (en) 2002-12-19 2004-07-08 Nektar Therapeutics Al, Corp. Cyanovirin variant-polymer conjugates
BRPI0407882B1 (pt) * 2003-02-26 2021-07-27 Nektar Therapeutics Composição compreendendo conjugados de polímero-porção de fator viii e seu método de fabricação
NZ542094A (en) * 2003-03-14 2008-12-24 Neose Technologies Inc Branched polymer conjugates comprising a peptide and water-soluble polymer chains
CA2571292C (en) * 2004-06-30 2013-05-21 Nektar Therapeutics Al, Corporation Polymer-factor ix moiety conjugates
PT2363414T (pt) * 2004-11-12 2022-08-04 Bayer Healthcare Llc Modificação de fviii direcionada a sítio
CN101163506B (zh) * 2004-12-27 2012-09-26 巴克斯特国际公司 聚合物-von Willebrand因子偶联物
WO2006114105A2 (en) * 2005-04-26 2006-11-02 Maxygen Holdings Ltd. Use of modified factor vii for treating bleeding
EP2975135A1 (en) * 2005-05-25 2016-01-20 Novo Nordisk A/S Glycopegylated factor IX
US7645860B2 (en) * 2006-03-31 2010-01-12 Baxter Healthcare S.A. Factor VIII polymer conjugates
AU2007245190B2 (en) 2006-03-31 2011-07-21 Takeda Pharmaceutical Company Limited Pegylated factor VIII
PT2101821E (pt) * 2006-12-15 2014-10-03 Baxter Int Fator conjugado viia-ácido (poli)siálico com prolongamento do tempo de meia vida in vivo
EP2114458B1 (en) 2006-12-27 2014-02-26 Nektar Therapeutics Von willebrand factor- and factor viii-polymer conjugates having a releasable linkage

Also Published As

Publication number Publication date
BRPI0920259A8 (pt) 2017-09-19
SI2349342T1 (sl) 2018-10-30
LT2349342T (lt) 2018-10-10
PT2349342T (pt) 2018-10-26
EP3437661A1 (en) 2019-02-06
JP5785872B2 (ja) 2015-09-30
WO2010045568A1 (en) 2010-04-22
EP3620177A1 (en) 2020-03-11
DK2349342T3 (en) 2018-10-08
US20100099616A1 (en) 2010-04-22
US20190160178A1 (en) 2019-05-30
BRPI0920259A2 (pt) 2016-01-05
US20120076749A1 (en) 2012-03-29
JP2012505917A (ja) 2012-03-08
HRP20181454T1 (hr) 2018-12-14
PL2349342T3 (pl) 2019-01-31
CY1120921T1 (el) 2019-12-11
HUE039906T2 (hu) 2019-02-28
KR101929641B1 (ko) 2018-12-14
SMT201800486T1 (it) 2018-11-09
CA2738679A1 (en) 2010-04-22
NZ592688A (en) 2012-12-21
AU2009305612A1 (en) 2010-04-22
MX2011004085A (es) 2011-09-27
EP2349342A1 (en) 2011-08-03
KR20110071012A (ko) 2011-06-27
AU2009305612B2 (en) 2015-05-21
US20160199503A1 (en) 2016-07-14
JP2015110676A (ja) 2015-06-18
KR20160103173A (ko) 2016-08-31
EP2349342B1 (en) 2018-06-27

Similar Documents

Publication Publication Date Title
ES2692172T3 (es) Factores sanguíneos modificados que comprenden un bajo grado de polímero soluble en agua
AU2005322067B2 (en) Polymer-von Willebrand factor-conjugates
US20120121613A1 (en) Protein conjugate having an endopeptidase- cleavable bioprotective moiety
JP7071093B2 (ja) 血液凝固タンパク質複合体
JP2015163650A (ja) 延長されたｉｎｖｉｖｏ半減期を有する第ＶＩＩａ因子−（ポリ）シアル酸結合体
ES2515365T3 (es) Procedimiento y composiciones para detectar específicamente moléculas poliméricas fisiológicamente aceptables
HK1127300A (en) Pegylated factor viii
HK1105276B (en) Polymer-von willebrand factor-conjugates